Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Subscribe To Our Newsletter & Stay Updated
